166 related articles for article (PubMed ID: 17159126)
1. Neurologic and hematologic response to fludarabine treatment in IgM MGUS polyneuropathy.
Niermeijer JM; Eurelings M; Lokhorst H; Franssen H; Fijnheer R; Wokke JH; Notermans NC
Neurology; 2006 Dec; 67(11):2076-9. PubMed ID: 17159126
[TBL] [Abstract][Full Text] [Related]
2. Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy.
Niermeijer JM; Eurelings M; van der Linden MW; Lokhorst HM; Franssen H; Fischer K; Teunissen LL; van den Berg LH; Schobben F; Wokke JH; Notermans NC
Neurology; 2007 Jul; 69(1):50-9. PubMed ID: 17606880
[TBL] [Abstract][Full Text] [Related]
3. Prognosis of polyneuropathy due to IgM monoclonal gammopathy: a prospective cohort study.
Niermeijer JM; Fischer K; Eurelings M; Franssen H; Wokke JH; Notermans NC
Neurology; 2010 Feb; 74(5):406-12. PubMed ID: 20124206
[TBL] [Abstract][Full Text] [Related]
4. Intravenous cyclophosphamide in refractory polyneuropathy associated with IgM monoclonal gammopathy: an uncontrolled open trial.
Hamidou MA; Belizna C; Wiertlewsky S; Audrain M; Biron C; Grolleau JY; Mussini JM
Am J Med; 2005 Apr; 118(4):426-30. PubMed ID: 15808143
[No Abstract] [Full Text] [Related]
5. Characterizing neuropathies associated with monoclonal gammopathy of undetermined significance (MGUS): a framework consistent with classifying injuries according to fiber size.
Fisher MA; Wilson JR
Neurol Clin Neurophysiol; 2002; 2002(3):2-7. PubMed ID: 12028821
[TBL] [Abstract][Full Text] [Related]
6. Long-term response to rituximab and fludarabine combination in IgM anti-myelin-associated glycoprotein neuropathy.
Gruson B; Ghomari K; Beaumont M; Garidi R; Just A; Merle P; Merlusca L; Marolleau JP; Royer B
J Peripher Nerv Syst; 2011 Sep; 16(3):180-5. PubMed ID: 22003932
[TBL] [Abstract][Full Text] [Related]
7. Cladribine in the treatment of IgM paraproteinemic polyneuropathy.
Ghosh A; Littlewood T; Donaghy M
Neurology; 2002 Oct; 59(8):1290-1. PubMed ID: 12391375
[No Abstract] [Full Text] [Related]
8. Intermittent cyclophosphamide and prednisone treatment of polyneuropathy associated with monoclonal gammopathy of undetermined significance.
Notermans NC; Lokhorst HM; Franssen H; Van der Graaf Y; Teunissen LL; Jennekens FG; Van den Berg LH; Wokke JH
Neurology; 1996 Nov; 47(5):1227-33. PubMed ID: 8909434
[TBL] [Abstract][Full Text] [Related]
9. [Polyneuropathies and dysglobulinemias].
Ferrer S; Jiménez C
Rev Med Chil; 1994 Apr; 122(4):448-53. PubMed ID: 7809541
[TBL] [Abstract][Full Text] [Related]
10. Immunoglobulin gene analysis in polyneuropathy associated with IgM monoclonal gammopathy.
Eurelings M; Notermans NC; Lokhorst HM; van Kessel B; Jacobs BC; Wokke JH; Sahota SS; Bloem AC
J Neuroimmunol; 2006 Jun; 175(1-2):152-9. PubMed ID: 16600385
[TBL] [Abstract][Full Text] [Related]
11. Rituximab for polyneuropathy with IgM monoclonal gammopathy.
Niermeijer JM; Eurelings M; Lokhorst HL; van der Pol WL; Franssen H; Wokke JH; Notermans NC
J Neurol Neurosurg Psychiatry; 2009 Sep; 80(9):1036-9. PubMed ID: 19684235
[TBL] [Abstract][Full Text] [Related]
12. Sural nerve T cells in demyelinating polyneuropathy associated with monoclonal gammopathy.
Eurelings M; Notermans NC; Wokke JH; Bosboom WM; Van den Berg LH
Acta Neuropathol; 2002 Feb; 103(2):107-14. PubMed ID: 11810175
[TBL] [Abstract][Full Text] [Related]
13. Fludarabine may overcome resistance to rituximab in IgM-related neuropathy.
Koya J; Iwata A; Nakamura F; Nagashima Y; Ichikawa M; Tsuji S; Kurokawa M
J Neurol Sci; 2012 Apr; 315(1-2):150-2. PubMed ID: 22236889
[TBL] [Abstract][Full Text] [Related]
14. Length dependence in polyneuropathy associated with IgM gammopathy.
Franssen H; Notermans NC
Ann Neurol; 2006 Feb; 59(2):365-71. PubMed ID: 16437567
[TBL] [Abstract][Full Text] [Related]
15. Prevalence, specificity and functionality of anti-ganglioside antibodies in neuropathy associated with IgM monoclonal gammopathy.
Stork AC; Jacobs BC; Tio-Gillen AP; Eurelings M; Jansen MD; van den Berg LH; Notermans NC; van der Pol WL
J Neuroimmunol; 2014 Mar; 268(1-2):89-94. PubMed ID: 24529728
[TBL] [Abstract][Full Text] [Related]
16. Malignant transformation in polyneuropathy associated with monoclonal gammopathy.
Eurelings M; Lokhorst HM; Kalmijn S; Wokke JH; Notermans NC
Neurology; 2005 Jun; 64(12):2079-84. PubMed ID: 15985576
[TBL] [Abstract][Full Text] [Related]
17. IgE response in multiple myeloma.
Tamir R; Barchat I; Weiss H; Pick AI
Ann Allergy; 1993 Mar; 70(3):214-7. PubMed ID: 8452316
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal gammopathy of undetermined significance (MGUS) in patients with solid tumors: effects of chemotherapy on the monoclonal protein.
Anagnostopoulos A; Galani E; Gika D; Sotou D; Evangelopoulou A; Dimopoulos MA
Ann Hematol; 2004 Oct; 83(10):658-60. PubMed ID: 15278296
[TBL] [Abstract][Full Text] [Related]
19. Classical and lectin complement pathway activity in polyneuropathy associated with IgM monoclonal gammopathy.
Stork AC; Cats EA; Vlam L; Heezius E; Rooijakkers S; Herpers B; de Jong BA; Rijkers G; van Strijp J; Notermans NC; van den Berg LH; van der Pol WL
J Neuroimmunol; 2016 Jan; 290():76-9. PubMed ID: 26711574
[TBL] [Abstract][Full Text] [Related]
20. Long-term effect of rituximab in anti-mag polyneuropathy.
Benedetti L; Briani C; Franciotta D; Carpo M; Padua L; Zara G; Zambello R; Sormani MP; Mancardi GL; Nobile-Orazio E; Schenone A
Neurology; 2008 Nov; 71(21):1742-4. PubMed ID: 19015493
[No Abstract] [Full Text] [Related]
[Next] [New Search]
